Dianthus Therapeutics extends rally after boosted $251 mln equity raise

Dianthus Therapeutics

10/09/2025 13:04

**  Dianthus Therapeutics' DNTH.O shares up 7.1% premarket to $38.08 after above-target equity haul

** New York City-headquartered Dianthus late Tues announced pricing ~7.6 mln shares, including ~1.1 mln pre-funded warrants, for ~$251 mln gross proceeds

** Offering price of $33 is 7.2% discount to stock's last sale on Tues

** DNTH shares on Mon rose 20% after co's mid-stage trial win for its muscle-weakening drug claseprubart

** And its stock on Tues finished up ~12% at an over 3-yr high as co marketed a $150 mln offering to fund preclinical and clinical development activities, and for working capital and general purposes

** Jefferies, TD Cowen, Evercore and Stifel are joint bookrunners for the offering

** Through Tues, shares up ~90% over the past three months, putting them up ~63% in 2025

** Avg rating among 13 analysts is "strongbuy" and median PT is $51.50, per LSEG data

 (Lance Tupper is a Reuters market analyst. The views expressed are his own)

 ((lance.tupper@tr.com 1-646-279-6380))